Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed the day trading at $0.57 down -10.40% from the previous closing price of $0.64. In other words, the price has decreased by -$10.40 from its previous closing price. On the day, 1.62 million shares were traded. XFOR stock price reached its highest trading level at $0.6558 during the session, while it also had its lowest trading level at $0.57.
Ratios:
For a better understanding of XFOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.80 and its Current Ratio is at 4.89. In the meantime, Its Debt-to-Equity ratio is 1.31 whereas as Long-Term Debt/Eq ratio is at 1.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 15 ’24 when Ragan Paula sold 31,897 shares for $0.39 per share. The transaction valued at 12,583 led to the insider holds 993,919 shares of the business.
Ragan Paula bought 31,897 shares of XFOR for $13,078 on Nov 15 ’24. On Oct 15 ’24, another insider, Ragan Paula, who serves as the President and CEO of the company, sold 31,897 shares for $0.56 each. As a result, the insider received 17,926 and left with 1,025,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 97228280 and an Enterprise Value of 9242562. For the stock, the TTM Price-to-Sale (P/S) ratio is 86.81 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 16.417 whereas that against EBITDA is -0.075.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.13, which has changed by -0.280303 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $1.60, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 4.12%, while the 200-Day Moving Average is calculated to be -26.71%.
Shares Statistics:
Over the past 3-months, XFOR traded about 3.44M shares per day on average, while over the past 10 days, XFOR traded about 2565890 shares per day. A total of 168.51M shares are outstanding, with a floating share count of 117.85M. Insiders hold about 30.90% of the company’s shares, while institutions hold 35.60% stake in the company. Shares short for XFOR as of 1730332800 were 11424210 with a Short Ratio of 3.88, compared to 1727654400 on 13562227. Therefore, it implies a Short% of Shares Outstanding of 11424210 and a Short% of Float of 6.84.
Earnings Estimates
The current assessment of X4 Pharmaceuticals Inc (XFOR) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.14 and -$0.16 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is -$0.49, with 5.0 analysts recommending between -$0.09 and -$0.7.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $2.53M. There is a high estimate of $4.7M for the next quarter, whereas the lowest estimate is $1.4M.
Based on 6 analysts’ estimates, the company’s revenue will be $16.55M in the next fiscal year. The high estimate is $23.5M and the low estimate is $7.81M.
